Drug Trial Radar · NCT06727734
Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception
Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
980
Planned (sponsor's estimate)
Start
Jan 18, 2025
Primary completion
Sep 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- The University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Family Planning Association of Hong Kong
- First posted
- Dec 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare the failure rate of the levonorgestrel (LNG)-piroxicam combination regimen versus ulipristal acetate (UPA) as emergency contraception (EC). The main questions it aims to answer are: 1. whether the LNG-piroxicam combination regimen has a lower failure rate than UPA for EC; 2. whether the LNG-piroxicam combination regimen has a higher percentage of pregnancies prevented than UPA for EC 3. whether there is any difference in the change in the subsequent menstrual cycle and adverse effect profile between the two regimens Participants will: 1. Take a single dose of either (i) LNG 1.5 mg plus piroxicam 40 mg and a placebo tablet resembling UPA, or (ii) UPA 30 mg plus placebo tablets resembling LNG and piroxicam. 2. Have a blood test for serum LH, oestradiol an progesterone. 3. Keep a diary of their vaginal bleeding episodes, adverse effects symptoms, any further acts of intercourse and the type of contraception used. 4. Have a follow-up either in person by phone about 1-2 weeks after the next expected menstruation. 5. If normal menstrual bleeding has not occurred by that time, a pregnancy test will be carried out.
Conditions
- Contraception
Interventions
LevonorgestrelDrug
Levonorgestrel 1.5 mg
PiroxicamDrug
Piroxicam 40 mg
Ulipristal AcetateDrug
Ulipristal 30 mg
Placebo - LNGDrug
Placebo of levonorgestrel
Placebo - PiroxicamDrug
Placebo of piroxicam
Placebo - UPADrug
Placebo of ulipristal acetate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pregnancy rateTime frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Family Planning Association of Hong Kong
Hong Kong, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.